Market Research Reports, Inc. has announced the addition of “End-Stage Kidney Disease - Pipeline Review, H1 2017” research report to their website www.MarketResearchReports.com

Lewes, DE -- (SBWire) -- 06/12/2017 --End-Stage Kidney Disease - Pipeline Review, H1 2017, provides an overview of the End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.

End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant.

Report Highlights
Publisher's Pharmaceutical and Healthcare latest pipeline guide End-Stage Kidney Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase I, IND/CTA Filed and Preclinical stages are 1, 4, 1 and 2 respectively.

End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of End-Stage Kidney Disease (Genito Urinary System And Sex Hormones).

- The pipeline guide reviews pipeline therapeutics for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 54 pages "End-Stage Kidney Disease - Pipeline Review, H1 2017" report covers Introduction, Report Coverage, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview, End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Development, Pipeline Overview, Pipeline by Companies, Appendix. This report Covered Companies - BLR Bio LLC, CTI BioPharma Corp, F. Hoffmann-La Roche Ltd, Novartis AG, Prolong Pharmaceuticals LLC, VESSL Therapeutics Ltd.

Please visit this link for more details: http://www.marketresearchreports.com/global-markets-direct/end-stage-kidney-disease-pipeline-review-h1-2017

Related Reports;

Systemic Lupus Erythematosus - Pipeline Review, H1 2017 - Visiit at - http://www.marketresearchreports.com/global-markets-direct/systemic-lupus-erythematosus-pipeline-review-h1-2017

Lung Transplant Rejection - Pipeline Review, H1 2017 - Visit at - http://www.marketresearchreports.com/global-markets-direct/lung-transplant-rejection-pipeline-review-h1-2017

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

About Market Research Reports, Inc.
Market Research Reports® Inc. is world's largest store offering quality market research, SWOT analysis, competitive intelligence and industry reports. We help Fortune 500 to Start-Ups with the latest market research reports on global & regional markets which comprise key industries, leading market players, new products and latest industry analysis & trends.

Contact us for your market research requirements: http://www.marketresearchreports.com/contact